Eckert & Ziegler Strahlen- und Medizintechnik AG received approval for its pharmaceutical Ge/Ga generator GalliaPharm from the Brazilian health authority ANVISA. GalliaPharm is thus the first and currently the only pharmaceutical gallium generator approved in Brazil. GalliaPharm is already successfully used in combination with approved kits, for the diagnosis of neuroendocrine tumors and in clinical trials also for prostate cancer. In Brazil, more than 590.000 new cases of cancer have been reported in 2020, with 97.278 in prostate, followed by breast and colorectum cancer. Gallium generators offer a low-cost alternative to radioactive labeling of biomolecules with gallium-68 in PET, an imaging examination method used to detect the presence or absence of diseased tissue. The procedure is used primarily in the diagnosis of cancer, heart attacks or neurological diseases. Up to now, the radioisotopes fluorine-18 or carbon-11 have mostly been used to label biomolecules. This requires millions of dollars of investment in large-scale equipment. The Ge/Ga generator, on the other hand, is about the size of a thermos flask and can be obtained much more cheaply, which reduces costs and increases flexibility in nuclear medical clinics and practices.